June 8, 2020 Uncategorized

Xylem reports broad sustainability advances, beats greenhouse gas reduction target by more than 40%

RYE BROOK, N.Y.–(BUSINESS WIRE)–Jun. 8, 2020– Xylem Inc. (NYSE:XYL), a global water technology company, today announced it had succeeded in reducing greenhouse gas emissions (GHG) intensity, exceeding its planned target. Xylem’s 2019 Sustainability Report, “Water for a Healthy World,” launched today, revealed the Company had achieved a 28.3% reduction in GHG intensity, against a target... Read more

May 29, 2020 Uncategorized

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer

      ·Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy in Europe Basel, 29 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted... Read more

May 29, 2020 Uncategorized

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer

Basel, 29 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa... Read more

May 28, 2020 Uncategorized

Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe

             Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human... Read more

May 20, 2020 Uncategorized

Looking Closely at Germ Cell Development

Researchers use superresolution to better understand the formation of germ granules Germ cells are special types of stem cells that give rise to sperm and egg – the cells that combine during reproduction to create the next generation. Dr. Alexey Arkov and his lab at Murray State University (USA) work to better understand the molecules... Read more

May 16, 2020 Uncategorized

Business Wire’s Website is Currently Unavailable

Business Wire We apologize for the inconvenience. Our team is working to resolve the issue. If you have questions or need to submit a news release, please contact your local Business Wire bureau: US: +1.888.381.WIRE(9473) Australia: +61 2.9004.7015 Canada: +1.416.593.0208 France: +33 1.56.88.29.40 Germany: +49 69.915066.0 Hong Kong: +852.3602.3091 Japan: +81 3.3239.0755 UK: +44 20.7626.1982 Read more

May 11, 2020 Uncategorized

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 11 May 2020 Roche today announced that Michael Varney (1958) Ph.D., and Head of Genentech Research and Early Development (gRED) since 2015, will retire from the company at the end of July.  Aviv Regev (1971), Ph.D., and currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the... Read more